Genomic testing is one of the most advanced forms of medical diagnostics. It helps identify genetic risks, detect diseases early, and guide personalised treatment. However, in India, these tests have remained expensive and out of reach for most people. Reliance now aims to change that by making genomic testing affordable for the masses.
The company plans to use the expertise of Strand Life Sciences, a Bengaluru‑based genomics and diagnostics firm that Reliance acquired in 2021. With this partnership, Reliance is preparing to enter the specialised world of genetic testing at a scale never seen before.
A Tenfold Price Drop Could Change Everything
Reports indicate that Reliance is working on offering basic genomic tests for below ₹1,000, compared to the current market price of around ₹10,000. This dramatic price reduction could:
- Make advanced diagnostics accessible to millions of Indians
- Boost early disease detection, especially for cancer, heart disease, and rare disorders
- Reduce healthcare costs for families
- Expand preventive healthcare across urban and rural India
Experts believe that if Reliance scales this model nationwide, it could reshape the diagnostics industry just as Jio reshaped telecom.
Strand Life Sciences: The Engine Behind the Plan
Reliance’s entry into genomics is powered by Strand Life Sciences, which it acquired for ₹393 crore in 2021. Strand has years of experience in:
- DNA sequencing
- Genetic risk analysis
- Precision medicine
- Specialised diagnostic testing
By combining Strand’s scientific expertise with Reliance’s massive distribution network, the company aims to bring high‑quality genomic testing to every corner of India.
A Potential “Jio Moment” for Healthcare
Industry analysts say this move mirrors the strategy behind Jio:
- High technology
- Low pricing
- Mass adoption
If Reliance succeeds, India could see a new era of affordable precision healthcare, where genetic testing becomes as common as routine blood tests.
For now, the industry is watching closely as Reliance prepares to roll out this ambitious plan one that could redefine the future of diagnostics in India.
